Insider Action On Hong Kong's Undervalued Small Caps For October 2024

In This Article:

As geopolitical tensions in the Middle East escalate, global markets have experienced volatility, with Hong Kong's Hang Seng Index climbing 10.2% amid optimism about Beijing's support measures. In this environment of fluctuating market sentiment, identifying promising small-cap stocks in Hong Kong requires a keen understanding of economic indicators and insider activities that may signal potential opportunities.

Top 5 Undervalued Small Caps With Insider Buying In Hong Kong

Name

PE

PS

Discount to Fair Value

Value Rating

Edianyun

NA

0.8x

24.79%

★★★★★☆

Ferretti

10.7x

0.7x

47.78%

★★★★☆☆

Hang Lung Group

7.7x

1.3x

49.46%

★★★★☆☆

Gemdale Properties and Investment

NA

0.3x

34.12%

★★★★☆☆

Vesync

8.0x

1.2x

-15.03%

★★★☆☆☆

Beijing Chunlizhengda Medical Instruments

17.0x

3.8x

38.45%

★★★☆☆☆

China Lesso Group Holdings

7.3x

0.5x

-643.31%

★★★☆☆☆

Skyworth Group

6.8x

0.1x

-379.03%

★★★☆☆☆

Guangdong Kanghua Healthcare Group

13.7x

0.3x

5.82%

★★★☆☆☆

Click here to see the full list of 9 stocks from our Undervalued SEHK Small Caps With Insider Buying screener.

Let's take a closer look at a couple of our picks from the screened companies.

Hang Lung Group

Simply Wall St Value Rating: ★★★★☆☆

Overview: Hang Lung Group is primarily engaged in property sales and leasing in Hong Kong and Mainland China, with a market capitalization of HK$24.92 billion.

Operations: The company's revenue primarily stems from property sales and leasing activities in Hong Kong and Mainland China. Over recent periods, the gross profit margin has shown fluctuations, with a notable decrease to 63.42% as of June 30, 2024. Operating expenses have remained relatively stable compared to other costs, while non-operating expenses have varied significantly, impacting net income margins.

PE: 7.7x

Hang Lung Group, a smaller player in Hong Kong's market, has caught attention with insider confidence shown by Wenbwo Chan purchasing 200,000 shares for HK$1.93 million between July and October 2024. Despite recent earnings challenges—net income for H1 2024 was HK$888 million compared to HK$1.68 billion last year—the company maintains its dividend at HK$0.21 per share. While earnings have declined by an average of 12% annually over the past five years, sales have grown to HK$6.38 billion from HK$5.53 billion year-on-year, suggesting potential resilience amid financial pressures primarily due to higher-risk external borrowing sources without customer deposits backing liabilities.